(NAGE) Niagen Bioscience - Overview
Stock: NAD+ Precursors, Supplement, Test Kits, Reference Standards
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 77.7% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.18 |
| Alpha | -30.96 |
| Character TTM | |
|---|---|
| Beta | 1.581 |
| Beta Downside | 1.224 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.40% |
| CAGR/Max DD | 0.64 |
Description: NAGE Niagen Bioscience January 26, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a U.S.-based bioscience firm that focuses on products aimed at supporting healthy aging, primarily through its proprietary nicotinamide riboside (NR) ingredient branded as NIAGEN.
The company operates in three segments: (1) Consumer products – finished dietary supplements sold via its own e-commerce site (TRU NIAGEN.com), Amazon, ShopHQ, specialty retailers and health-care practitioners; (2) Ingredients – food-grade and pharmaceutical-grade NIAGEN sold as raw material to other manufacturers; and (3) Analytical Reference Standards & Services – NAD⁺ test kits for clinicians and phytochemical reference standards for R&D.
According to the FY 2025 earnings release (filed March 2026), NAGE generated $112 million in revenue, a 22 % YoY increase driven largely by a 35 % rise in ingredient sales to third-party supplement makers. Gross margin expanded to 68 % (up from 63 % in FY 2024) as the company leveraged higher-volume contracts and improved manufacturing yields. Cash and short-term investments stood at $84 million, providing ~18 months of runway at current burn rates.
Sector-level data show the global NAD⁺ precursor market was valued at $1.4 billion in 2024 and is projected to grow at a CAGR of 12 % through 2030, propelled by an aging-population demographic (U.S. adults 65+ expected to reach 23 % of the population by 2035) and increasing scientific validation of NR’s role in cellular metabolism. However, the market remains sensitive to regulatory scrutiny; the FDA’s 2025 guidance on “new dietary ingredient” substantiation could affect product labeling and claim permissions.
Key risks include heavy reliance on a single flagship ingredient (NR), which concentrates both commercial and regulatory exposure, and competitive pressure from emerging NAD⁺ boosters such as nicotinamide mononucleotide (NMN) that are gaining traction in both consumer and pharmaceutical pipelines. A material adverse change in reimbursement policy for NAD⁺ testing kits would also compress the analytical services segment’s margins.
For a data-driven, risk-adjusted view of NAGE’s valuation relative to its peers, you may find it useful to explore the analytics platform ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 20.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 14.37 > 1.0 |
| NWC/Revenue: 56.86% < 20% (prev 37.56%; Δ 19.29% < -1%) |
| CFO/TA 0.22 > 3% & CFO 21.4m > Net Income 20.4m |
| Net Debt (-61.1m) to EBITDA (21.1m): -2.89 < 3 |
| Current Ratio: 4.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.6m) vs 12m ago 11.38% < -2% |
| Gross Margin: 63.89% > 18% (prev 0.61%; Δ 6328 % > 0.5%) |
| Asset Turnover: 161.3% > 50% (prev 162.2%; Δ -0.91% > 0%) |
| Interest Coverage Ratio: -14.36 > 6 (EBITDA TTM 21.1m / Interest Expense TTM -1.38m) |
Altman Z'' -5.58
| A: 0.72 (Total Current Assets 93.6m - Total Current Liabilities 22.7m) / Total Assets 98.1m |
| B: -1.72 (Retained Earnings -168.7m / Total Assets 98.1m) |
| C: 0.26 (EBIT TTM 19.9m / Avg Total Assets 77.3m) |
| D: -6.14 (Book Value of Equity -168.6m / Total Liabilities 27.5m) |
| Altman-Z'' Score: -5.58 = D |
Beneish M -3.21
| DSRI: 0.88 (Receivables 8.51m/7.10m, Revenue 124.7m/91.7m) |
| GMI: 0.96 (GM 63.89% / 61.45%) |
| AQI: 0.50 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.36 (Revenue 124.7m / 91.7m) |
| TATA: -0.01 (NI 20.4m - CFO 21.4m) / TA 98.1m) |
| Beneish M-Score: -3.21 (Cap -4..+1) = AA |
What is the price of NAGE shares?
Over the past week, the price has changed by -13.19%, over one month by -23.08%, over three months by -21.21% and over the past year by -8.61%.
Is NAGE a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NAGE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.8 | 203.8% |
| Analysts Target Price | 15.8 | 203.8% |
| ValueRay Target Price | 5.4 | 4.2% |
NAGE Fundamental Data Overview February 04, 2026
P/E Forward = 19.9601
P/S = 3.8972
P/B = 6.7638
Revenue TTM = 124.7m USD
EBIT TTM = 19.9m USD
EBITDA TTM = 21.1m USD
Long Term Debt = 3.06m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 978.0k USD (from shortTermDebt, last quarter)
Debt = 3.06m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -61.1m USD (from netDebt column, last quarter)
Enterprise Value = 424.9m USD (486.0m + Debt 3.06m - CCE 64.1m)
Interest Coverage Ratio = -14.36 (Ebit TTM 19.9m / Interest Expense TTM -1.38m)
EV/FCF = 20.09x (Enterprise Value 424.9m / FCF TTM 21.1m)
FCF Yield = 4.98% (FCF TTM 21.1m / Enterprise Value 424.9m)
FCF Margin = 16.96% (FCF TTM 21.1m / Revenue TTM 124.7m)
Net Margin = 16.38% (Net Income TTM 20.4m / Revenue TTM 124.7m)
Gross Margin = 63.89% ((Revenue TTM 124.7m - Cost of Revenue TTM 45.0m) / Revenue TTM)
Gross Margin QoQ = 64.52% (prev 65.00%)
Tobins Q-Ratio = 4.33 (Enterprise Value 424.9m / Total Assets 98.1m)
Interest Expense / Debt = 0.16% (Interest Expense 5000 / Debt 3.06m)
Taxrate = 4.62% (222.0k / 4.80m)
NOPAT = 18.9m (EBIT 19.9m * (1 - 4.62%))
Current Ratio = 4.12 (Total Current Assets 93.6m / Total Current Liabilities 22.7m)
Debt / Equity = 0.04 (Debt 3.06m / totalStockholderEquity, last quarter 70.7m)
Debt / EBITDA = -2.89 (Net Debt -61.1m / EBITDA 21.1m)
Debt / FCF = -2.89 (Net Debt -61.1m / FCF TTM 21.1m)
Total Stockholder Equity = 59.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.42% (Net Income 20.4m / Total Assets 98.1m)
RoE = 34.58% (Net Income TTM 20.4m / Total Stockholder Equity 59.1m)
RoCE = 31.98% (EBIT 19.9m / Capital Employed (Equity 59.1m + L.T.Debt 3.06m))
RoIC = 32.07% (NOPAT 18.9m / Invested Capital 59.1m)
WACC = 11.67% (E(486.0m)/V(489.1m) * Re(11.74%) + D(3.06m)/V(489.1m) * Rd(0.16%) * (1-Tc(0.05)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.39%
[DCF Debug] Terminal Value 55.89% ; FCFF base≈14.3m ; Y1≈9.46m ; Y5≈4.37m
Fair Price DCF = 1.43 (EV 52.9m - Net Debt -61.1m = Equity 113.9m / Shares 79.8m; r=11.67% [WACC]; 5y FCF grow -39.53% → 2.90% )
EPS Correlation: 80.88 | EPS CAGR: 176.0% | SUE: -1.13 | # QB: 0
Revenue Correlation: 94.05 | Revenue CAGR: 18.90% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+38.9% | Growth Revenue=+20.4%